Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13187306 | 0.85 | S1PR1 (0.68) | S1PR1TP53POLB | |
| SCHEMBL2806750 | 0.83 | S1PR1 (0.71) | S1PR1TP53POLBCA12CA1 | |
| SCHEMBL27828743 | 0.83 | S1PR1 (0.68) | S1PR1TP53POLB | |
| SCHEMBL27851610 | 0.81 | S1PR1 (0.68) | S1PR1TP53POLB | |
| SCHEMBL2774195 | 0.81 | S1PR1 (0.67) | S1PR1TP53POLB | |
| SCHEMBL2787960 | 0.81 | S1PR1 (0.67) | S1PR1TP53POLB | |
| SCHEMBL13187637 | 0.80 | S1PR1 (0.64) | S1PR1TP53POLB | |
| SCHEMBL9968891 | 0.80 | S1PR1 (0.66) | S1PR1TP53POLB | |
| SCHEMBL10246640 | 0.80 | S1PR1 (0.68) | S1PR1TP53POLB | |
| SCHEMBL27919264 | 0.79 | S1PR1 (0.60) | S1PR1TP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2193125-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-01-11 | — | — | EP | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-8202865-B2 | Oxadiazole derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
| US-20100240658-A1 | Oxadiazole Derivatives | MERCK SERONO SA (CH) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240658-A1 | Oxadiazole Derivatives | OXA1L, RO60, NQO2 | S1PR1 483/4885TP53 2578/4885POLB 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.